FUnctionally different HTLV I-infected T cell lines with the same phenotype derived from a patient with melanomaSIVANANDHAM, M; MUKHERJI, B.Immunology letters. 1989, Vol 23, Num 2, pp 149-154, issn 0165-2478Article

T-cell clones that react against autologous human tumorsBIJAY MUKHERJI; CHAKRABORTY, N. G; SIVANANDHAM, M et al.Immunological reviews. 1990, Num 116, pp 33-62, issn 0105-2896, 30 p.Article

Adjuvant immunotherapy for patients with melanoma : Are patients with melanoma of the head and neck candidates for this therapy ?SHAW, P. M; SIVANANDHAM, M; BERNIK, S. F et al.Head & neck. 1997, Vol 19, Num 7, pp 595-603, issn 1043-3074Conference Paper

Tumor imaging of Dalton's lymphoma using antibody-desferal-Ga-67 complexUDAYACHANDER, M; MEENAKSHI, A; SIVANANDHAM, M et al.International journal of radiation oncology, biology, physics. 1989, Vol 16, Num 3, pp 731-736, issn 0360-3016Article

Tumor targeting potential of liposomes encapsulating Ga-67 and antibody to Dalton's lymphoma associated antigen (anti-DLAA)UDAYACHANDER, M; MEENAKSHI, A; MUTHIAH, R et al.International journal of radiation oncology, biology, physics. 1987, Vol 13, Num 11, pp 1713-1719, issn 0360-3016Article

Clonal expansion of T cells following in vitro stimulation with autologous melanoma cells and interleukin-2 studied by molecular analysis of a T cell receptorSIVANANDHAM, M; CHAKRABORTY, N. G; ROBBINS, G. R et al.Immunology letters. 1991, Vol 28, Num 2, pp 155-159, issn 0165-2478, 5 p.Article

Clonal analysis of cytotoxic and regulatory T cell responses against human melanomaBIJAY MUKHERJI; GUHA, A; CHAKRABORTY, N. G et al.The Journal of experimental medicine. 1989, Vol 169, Num 6, pp 1961-1976, issn 0022-1007Article

Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukln-2 induce antitumor response in syngeneic miceSIVANANDHAM, M; SHAW, P; BERNIK, S. F et al.Cancer immunology and immunotherapy. 1998, Vol 46, Num 5, pp 261-267, issn 0340-7004Article

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine : Second interim analysis of data from a phase III, multi-institutional trialWALLACK, M. K; SIVANANDHAM, M; RICHARDS, J. M et al.Annals of surgery. 1997, Vol 226, Num 2, pp 198-206, issn 0003-4932Article

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma : The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. CommentaryWALLACK, M. K; SIVANANDHAM, M; ROSEN, L et al.Journal of the American College of Surgeons. 1998, Vol 187, Num 1, pp 69-79, issn 1072-7515Conference Paper

Active specific immunotherapy with vaccinia melanoma oncolysate for patients with melanoma : An overviewSIVANANDHAM, M; DITARANTO, K; SHAW, P et al.Vaccine research. 1996, Vol 5, Num 4, pp 215-232, issn 1056-7909Article

Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic responseCHAKRABORTY, M. G; TWARDZIK, D. R; SIVANANDHAM, M et al.The Journal of immunology (1950). 1990, Vol 145, Num 7, pp 2359-2364, issn 0022-1767Article